ME Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 111695 min ago

@ $0.773

Išleistas: 14 vas. 2024 @ 22:29

Grąža: -35.26%

Ankstesnis signalas: vas. 14 - 17:21

Ankstesnis signalas: Pardavimas

Grąža: 3.62 %

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics...

Stats
Šios dienos apimtis	3.08M
Vidutinė apimtis	7.56M
Rinkos kapitalizacija	241.60M
EPS	$0 ( 2024-02-07 )
Kita pelno data	( $-0.150 ) 2024-05-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.450
ATR14	$0.00100 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-04-18	Hibbs Kathy L	Sell	38 548	Class A Common Stock
2024-04-18	Hibbs Kathy L	Sell	38 548	Stock Option (Right to Buy)
2024-04-04	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-04-04	Hibbs Kathy L	Sell	38 548	Class A Common Stock

INSIDER POWER
73.76
Last 100 transactions
Buy: 15 283 999 \| Sell: 2 077 892

Tūris Koreliacija

Ilgas: -0.06 (neutral)

Trumpas: -0.98 (very strong negative)

Signal:(35.976) Neutral

23andMe Holding Co. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

23andMe Holding Co. Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

-0.24
( neutral )

23andMe Holding Co. Finansinės ataskaitos

Annual	2022
Pajamos:	$299.49M
Bruto pelnas:	$134.50M (44.91 %)
EPS:	$-0.690

FY	2022
Pajamos:	$299.49M
Bruto pelnas:	$134.50M (44.91 %)
EPS:	$-0.690

FY	2022
Pajamos:	$271.89M
Bruto pelnas:	$132.95M (48.90 %)
EPS:	$-0.600

FY	2021
Pajamos:	$243.92M
Bruto pelnas:	$117.01M (47.97 %)
EPS:	$-0.398

Financial Reports:

No articles found.

23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.